Primary HPV test screening

Slides:

Advertisements

Similar presentations

P16INK4A expression and HPV-L1 detection in the uterine cervix: cyto-histological and immunoistochemical study M.A. Caponio, T. Addati, G. Giannone, *G.

Advertisements

Clinical Use of HPV DNA Testing Thomas C. Wright, Jr. College of Physicians and Surgeons of Columbia University.

ACCP Evidence base: Implications for policy and practice R. Sankaranarayanan MD Head, Screening Group World Health Organization (WHO) International Agency.

Ai Ling Tan Gynaecological Oncologist Ascot Clinic/ADHB NCSP UPDATE & PRIMARY HPV SCREENING.

HUMAN PAPILLOMA VIRUS and CERVICAL CARCINOMA Roger J Rand.

Interim Guidance for the Use of Human Papillomavirus DNA Testing as an Adjunct to Cervical Cytology for Screening Obstetrics and Gynecology, Volume 103,

HPV: How to prevent your patients from becoming my patients Katina Robison, MD Assistant Professor, Department of Obstetrics & Gynecology Director of Colposcopy.

Screening in Developed Countries Lynette Denny Gynaecology Oncology Unit Department Obstetrics & Gynaecology and Institute Infectious Diseases and Molecular.

Cervical Cancer Screening Recommendations 2012, FDA Panel 2014.

Screening for cervical cancer. Screening for cervical lesions Common disease Cancer is preventable Screening is easy MUST BE PERFORMED.

TEMPLATE DESIGN © Outcome of Large Loop Excision of Transformation Zone (LLETZ ) in women over forty at two London Hospitals.

PRINCess Trial Prediction of Regression in CIN2. Coordinating centre in Christchurch Mainly NZ but Sydney and Melbourne just completing their approval.

Breast cancer affects 1 in 8 women during their lives. 1 Population Statistics.

Date of download: 6/26/2016 From: Cost-Effectiveness of Human Papillomavirus Vaccination and Cervical Cancer Screening in Women Older Than 30 Years in.

New Technologies in cervical cancer screening Cosette Wheeler, University of New Mexico Albuquerque, New Mexico.

NORMAL HPV INFECTION HR-HPV INFECTION HR-HPV PERSISTENCE HG-CIN+ HR-HPV TEST PAP TEST HPV GENOTYPING HPV mRNA, p16-ink4a ScreeningTriageHistologic confirmation.

Contact: PRELIMINARY RESULTS OF FIRST HPV PRIMARY SCREENING PRIVATE SECTOR IN BUENOS AIRES FEMALE POPULATION R. Jiménez del Toro,

THE NEW CERVICAL CANCER SCREENING PROGRAM

Cervical Cancer Screening

Public Health England leads the NHS Screening Programmes

Fig. 1. Framework of developing a guideline for cervical cancer screening. ① Benefits of pap test screening, ② harms of pap test screening, ③ accuracy.

Cancer prevention and early detection

“The challenges of colposcopy in Eastern Europe and Central Asia”

Cancer prevention and early detection

Performance of mRNA- and DNA-based high-risk human papillomavirus assays in detection of high-grade cervical lesions ELINA VIRTANEN1, ILKKA KALLIALA2,3,

NEW SCREENING PROTOCOL WITH DUAL-STAINED CYTOLOGY TRIAGE

Colposcopic Biopsy Results of HPV 16 and 18 patients in Bartın

Cost-effectiveness Analysis for Cervical Cancer Screening Using HPV DNA Tests in Chile Franco Figueira S, BPharm student1; Cachoeira CV, MD, MBA1; Silva.

NHS Cervical Screening Programme Introducing HPV Triage

INTRODUCTION: CERVICAL CANCER SCREENING

Incidence of CIN2 and 3 and cervical cancer

2nd WORLD GYNECOLOGIC CANCER CONFERENCE

From: Inefficiencies and High-Value Improvements in U. S

Efficacy of random cervical biopsy and routine endocervical curettage in subjects with normal colposcopy.

Cancer prevention and early detection

Risk factors for cervical intraepithelial neoplasia recurrence after loop electrosurgical excision procedure in HIV-1-infected and non-infected women.

Clinical Case and Discussion Questions

HPV DNA SCREENING, FROM CO-TESTING

Retest in 12mo with HPV testing

Dr Sam Hibbitts HPV Research Team Obstetrics & Gynaecology

Updates on Pap Smear Guidelines 2014

M. Arbyn, P. J. F. Snijders, C. J. L. M. Meijer, J. Berkhof, K

QUIZ QUESTIONS 1) WHAT ARE THE TWO TYPES OF CERVICAL CANCER?

Prognostic value of human papillomavirus types 16 and 18 DNA physical status in cervical intraepithelial neoplasia A. Gradíssimo Oliveira, C. Delgado,

The Lancet Public Health

Prognostic value of human papillomavirus types 16 and 18 DNA physical status in cervical intraepithelial neoplasia A. Gradíssimo Oliveira, C. Delgado,

Nat. Rev. Clin. Oncol. doi: /nrclinonc

The performance of human papillomavirus DNA detection with type 16/18 genotyping by hybrid capture in primary test of cervical cancer screening: a cross-sectional.

Cervical cancer incidence can increase despite HPV vaccination

The performance of human papillomavirus DNA detection with type 16/18 genotyping by hybrid capture in primary test of cervical cancer screening: a cross-sectional.

Management of the Abnormal Pap Smear.

Detection of TERC Amplification in Cervical Epithelial Cells for the Diagnosis of High- Grade Cervical Lesions and Invasive Cancer Jing Jiang, Li-Hui.

Prevalence of Human Papillomavirus Infection in Unselected SurePath Samples Using the APTIMA HPV mRNA Assay Matejka Rebolj, Sarah Preisler, Ditte M.

Public Health England leads the NHS Screening Programmes

Volume 136, Issue 2, Pages (February 2015)

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1: Guidelines for primary cytology# screening in South Africa

Screening to Prevent Invasive Cervical Cancer (Resource-Stratified)

Cervical excisional treatment of young women: A population-based study

Necessity of A Centralized Cervical Cancer Screening Program in IRAN

SH-sheikhhasani Gyn-oncologist

528,000 new cases 266,000 death 90 % of the deaths in LMIC

Volume 153, Issue 1, Pages (April 2019)

HUMAN PAPILLOMA VIRUS and CERVICAL CARCINOMA

Lessons From Implementing a Telecolposcopy Program

The performance of OncoE6TM cervical test in detecting cervical

Modern cervical cancer screening

Fig. 3. The examinations consumed by the three cervical screening strategies to detect CIN2+/CIN3+. (A) The cases of CIN2+ detected by three current cervical.

Fig. 2. Three cervical screening strategies to detect CIN2+/CIN3+

The percentage of positive among all women (A), women with CIN2, or more severe diagnosis (CIN2+; sensitivity; B), and grade 3 (CIN3) or more severe diagnosis.

Presentation transcript:

Primary HPV test screening

cytology HPV

COBAS OPTIMA HC

COBAS HPV DNA OPTIMA mRNA E6,E7 HC

Primary Screening HPV test increase reduce cost complexity sensitivity

For example: ATHENA

HPV test primary screening Age 25 28% Age 30 24%

HPV TEST primary screening NPV: 100%

Cytology versus HPV testing for cervical cancer screening in the general population Cochrane Systematic Review - August 2017

Test Disease threshold studies Pooled sensitivity (95% CI) Pooled specificity (95% CI) CC (ASCUS+) CIN 2+ 16 65.87% (54.94 to 75.33) 96.28% (94.72 to 97.39) LBC (ASCUS+) 15 75.51% (66.57 to 82.68) 91.85% (88.43 to 94.32) CC (LSIL+) 9 62.84% (46.79‐76.50) 97.73% (96.09‐98.70) LBC (LSIL+) 10 70.33% (59.73 to 79.11) 96.20% (94.57 to 97.36) HC2 (1 pg/mL) 25 92.60% (99.45 to 95.30) 89.30% (87.03 to 91.20) PCR (> 12 types) 6 95.13% (89.50 to 97.84) 91.89% (83.79 to 96.13) APTIMA 3 92.66% (31.77 to 99.71) 93.31% (47.30 to 99.54) CIN 3+ 70.27% (57.87 to 80.30) 96.67% (94.56 to 98.00) 13 75.97% (64.72 to 84.49) 91.19% (87.21 to 94.01) 5 74.43% (67.81 to 80.10) 96.86% (94.87 to 98.10) 71.91% (51.68 to 86.00) 96.05% (93.53 to 97.60) 19 96.50% (94.00 to 97.90) 89.20% (86.70 to 91.30)

International Journal of Cancer Int J Cancer. 2018 May 1; 142(9): 1952–1958

MIDDLE INCOME COUNTRY 1000,000 women CIN 1: 708 CIN 2:285 CIN 3:436 INVASIVE :85 HPV INCIDENCE: 3.5% HC 2